The AMAG chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AMAG chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The AMAG stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View AMAG Detailed Price Forecast - CNN Money||View AMAG Detailed Summary - Google Finance|
|View AMAG Detailed Summary - Yahoo! Finance||View AMAG Stock Research & Analysis - Zacks.com|
|View AMAG Trends & Analysis - Trade-Ideas||View AMAG Major Holders - Barrons|
|View AMAG Call Transcripts - NASDAQ||View AMAG Breaking News & Analysis - Seeking Alpha|
|View AMAG Annual Report - CompanySpotlight.com||View AMAG OTC Short Report - OTCShortReport.com|
|View AMAG Fundamentals - TradeKing||View AMAG SEC Filings - Bar Chart|
|View Historical Prices for AMAG - The WSJ||View Performance/Total Return for AMAG - Morningstar|
|View the Analyst Estimates for AMAG - MarketWatch||View the Earnings History for AMAG - CNBC|
|View the AMAG Earnings - StockMarketWatch||View AMAG Buy or Sell Recommendations - MacroAxis|
|View the AMAG Bullish Patterns - American Bulls||View AMAG Short Pain Metrics - ShortPainBot.com|
|View AMAG Stock Mentions - StockTwits||View AMAG Stock Mentions - PennyStockTweets|
|View AMAG Stock Mentions - Twitter||View AMAG Investment Forum News - Investor Hub|
|View AMAG Stock Mentions - Yahoo! Message Board||View AMAG Stock Mentions - Seeking Alpha|
|View Insider Transactions for AMAG - SECform4.com||View Insider Transactions for AMAG - Insider Cow|
|View AMAG Major Holdings Summary - CNBC||View Insider Disclosure for AMAG - OTC Markets|
|View Insider Transactions for AMAG - Yahoo! Finance||View Institutional Holdings for AMAG - NASDAQ|
|View AMAG Stock Insight & Charts - FinViz.com||View AMAG Investment Charts - StockCharts.com|
|View AMAG Stock Overview & Charts - BarChart||View AMAG User Generated Charts - Trading View|
Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
Posted on Monday June 24, 2019
on Monday jumped and then pulled back after the biopharma was cleared by the U.S. Food and Drug Administration to market a drug to treat weakened sexual desire in women. Palatin shares were trading off 6.72% at $1.25. The FDA cleared Vyleesi, a treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder, Palatin said.
Palatin's stock rockets after FDA OK to market sexual desire disorder treatment
Posted on Monday June 24, 2019
Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc.'s treatment for hypoactive sexual desire disorder (HSDD) triggered a $60 million milestone payment. Trading volume was over 2.9 million shares, making Palatin's stock the most actively traded ahead of the open. The FDA granted marketing approval for AMAG's new drug application (NDA) for Vyleesi, which was developed by Palatin. AMAG's stock surged 8.1% ahead of the open. The company expects to receive the milestone payment in July. Based on the license agreement with AMAG, Palatin is also entitled to receive royalties on sales, ranging from high single-digit to low double-digit percentage ranges, and other milestone payments based on escalating annual sales thresholds. Palatin's stock has rallied 23% over the past 12 months and AMAG shares have tumbled 59%, while the S&P 500 has gained 7.1%.
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Posted on Saturday June 22, 2019
Biotech stocks came made upward moves last week after a rangebound period. Among big pharma companies, Merck & Co., Inc. (NYSE: MRK ) was a standout gainer, notching up 52-week highs in successive sessions, ...
AMAG stock rallies on FDA approval for drug to increase women's sex drive
Posted on Friday June 21, 2019
The U.S. Food and Drug Administration late Friday approved a drug to treat low libido in women, and shares of the company slated to market the medication, AMAG Pharmaceuticals Inc. , shot more than 16% in the extended session. The drug, Vyleesi, is aimed at premenopausal women in whom low sex drive causes distress. It comes in an auto-injecting pen that can be used ahead of sexual activity. Vyleesi is expected to be commercially available in September. AMAG licensed Vyleesi from Palatin Technologies Inc. and under the terms of their agreement the FDA approval triggers a $60 million payment to Palatin, plus tiered royalties tied to sales milestones. Shares of Palatin rallied 30% in the extended session. Both stocks ended the regular trading day more than 4% higher.